Abstract
Neonates are at risk for 3 major forms of leukemia in the first year of life: acute leukemia, juvenile myelomonocytic leukemia, and transient abnormal myelopoiesis associated with Down syndrome. These disorders are rare but generate interest due to aggressive clinical presentation, suboptimal response to current therapies, and fascinating biology. Each can arise as a result of unique constitutional and acquired genetic events. Genetic insights are pointing the way toward novel therapeutic approaches. This article reviews key epidemiologic, clinical, and molecular features of neonatal leukemias, focusing on risk stratification, treatment, and strategies for developing novel molecularly targeted approaches to improve future outcomes.
Original language | English (US) |
---|---|
Pages (from-to) | 15-33 |
Number of pages | 19 |
Journal | Clinics in Perinatology |
Volume | 48 |
Issue number | 1 |
DOIs | |
State | Published - Mar 2021 |
Keywords
- ALL
- AML
- Down syndrome
- JMML
- KMT2A
- Leukemia
- RAS
- TAM
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
- Obstetrics and Gynecology